<SEC-DOCUMENT>0000950103-25-013417.txt : 20251021
<SEC-HEADER>0000950103-25-013417.hdr.sgml : 20251021
<ACCEPTANCE-DATETIME>20251021080017
ACCESSION NUMBER:		0000950103-25-013417
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251021
DATE AS OF CHANGE:		20251021

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	9695002Y8420ZB8HJE29

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91173
		FILM NUMBER:		251405386

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVO NORDISK A S
		CENTRAL INDEX KEY:			0000353278
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		NOVO ALLE DK 2880
		CITY:			BAGSVAERD DENMARK
		STATE:			G7
		ZIP:			00000
		BUSINESS PHONE:		4544448888

	MAIL ADDRESS:	
		STREET 1:		NOVO ALLE DK 2880
		CITY:			BAGSVAERD DENMARK
		STATE:			G7
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVO NORDISK A/S
		DATE OF NAME CHANGE:	19900807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVO INDUSTRI A S /DENMARK/
		DATE OF NAME CHANGE:	19890811
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0000950103-20-001698</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: NOVO NORDISK A S -->
          <cik>0000353278</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>07/14/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001598599</issuerCik>
        <issuerName>Innate Pharma SA</issuerName>
        <issuerCusip>45781K105</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>117 Avenue de Luminy</com:street1>
          <com:street2>BP 30191</com:street2>
          <com:city>Marseille</com:city>
          <com:stateOrCountry>I0</com:stateOrCountry>
          <com:zipCode>13009</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Novo Nordisk A/S</reportingPersonName>
      <citizenshipOrOrganization>G7</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>8895649.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>8895649.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8895649.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.65</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Innate Pharma SA</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>117 Avenue de Luminy, BP 30191, Marseille, France, 13009</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Novo Nordisk A/S</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Novo Alle 1, DK-2880, Bagsvaerd Denmark</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Denmark</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>8,895,649</amountBeneficiallyOwned>
        <classPercent>9.65%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>8,895,649</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>8,895,649</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Novo Nordisk A/S</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Karsten Munk Knudsen</signature>
        <title>Karsten Munk Knudsen, Chief Financial Officer</title>
        <date>10/21/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
